SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is surging as investors react to a positive price target hike and a series of strategic multi-year deals aimed at expanding its AI infrastructure footprint. The community is heavily focused on the stock's robust momentum, with many traders debating the likelihood of a continued squeeze toward higher price levels versus potential overbought conditions.

XRP is a decentralized digital asset and the native token of the XRP Ledger, a Layer 1 blockchain designed for high-performance global payments. Its primary value proposition is offering a fast, cost-effective alternative to traditional banking systems by enabling near-instant cross-border settlements that finalize in three to five seconds. By serving as a neutral bridge asset between different fiat currencies, it helps financial institutions lower liquidity costs and eliminates the need for pre-funded accounts.  The network is unique because it utilizes a federated consensus protocol instead of energy-intensive mining or staking. This system achieves deterministic finality through a Unique Node List of trusted validators who must reach an eighty percent agreement threshold to permanently record transactions. This infrastructure supports a sustained throughput of 1,500 transactions per second and includes a built-in decentralized exchange that allows for the automated trading of any tokenized asset without intermediaries.  The project traces its origins back to 2004 with Ryan Fugger before being co-founded in its modern form by Jed McCaleb and Chris Larsen. The company, now known as Ripple, works with major financial institutions as partners and investors to build global payment solutions. To protect the network from spam, a small amount of XRP is burned during every transaction, and the token is further utilized by institutions as collateral to access traditional markets and manage digital asset infrastructure.  Institutional adoption of the asset reached a major milestone in November 2025 when the SEC approved the first wave of spot XRP ETFs. These products, offered by major issuers including Bitwise, Grayscale, 21Shares, Canary Capital, and Franklin Templeton, are now listed on prominent exchanges like the NYSE Arca, Nasdaq, and Cboe BZX. While Ripple remains a key contributor to the ecosystem, the underlying XRP Ledger continues to operate as an open-source and decentralized network.

Ripple

XRP is trending as investors monitor the progress of the CLARITY Act, with community sentiment divided between those anticipating a major regulatory-driven rally and skeptics wary of stagnant price action. The conversation is currently fueled by speculative institutional adoption news and debates over whether Ripple’s utility will finally trigger a decoupling from broader crypto market volatility.

MARA Holdings, Inc. is a digital asset technology company, which engages in mining cryptocurrencies with a focus on the Bitcoin ecosystem. It also deals with owning and operating bitcoin mining facilities or data centers, selling proprietary software or technology to third parties operating in the Bitcoin ecosystem, offering advisory and consulting services to support Bitcoin mining ventures in domestic and international jurisdictions, and generating electricity from renewable energy resources or methane gas capture to power Bitcoin mining projects. The company was founded on February 23, 2010 and is headquartered in Hallandale Beach, FL.

MARA Holdings Inc.

Marathon Digital Holdings Inc

Marathon Digital Holdings is trending as investors react to the company's pivot toward AI infrastructure and high-performance computing, while community members actively discuss its potential for a short squeeze amid high short interest. Market participants remain sharply divided, with some highlighting the company's strategic bitcoin balance sheet management and energy assets, while others express frustration over historical stock performance and leadership.

Navitas Semiconductor Corp. engages in the development of ultra-efficient gallium nitride (GaN) semiconductors. Its GaN power ICs integrate GaN power with drive, control and protection to enable charging, power density, and energy savings for mobile, consumer, enterprise, eMobility and new energy markets. The company was founded by Daniel Kinzer, Nick Fichtenbaum, Gene Sheridan, and Jason Zhang on August 12, 2020 and is headquartered in Torrance, CA.

Navitas Semiconductor Corp

Navitas Semiconductor is trending as traders speculate on potential partnerships at upcoming tech conferences and analyze the impact of new power chip technologies on AI data center infrastructure. The community is actively debating the stock's consolidation patterns, recent institutional buying activity, and the potential for a breakout driven by increased demand for energy-efficient semiconductor solutions.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health is experiencing a strong rally fueled by optimistic community sentiment regarding the potential FDA reclassification of several peptides, which could significantly expand the company's product offerings and addressable market. Investors are actively discussing the stock's high short interest and technical breakouts, leading many to speculate that a potential short squeeze could drive the share price toward higher resistance levels.

Operates as a holding company with interest in providing social shopping platform solutions

WeShop Holdings Ltd - Ordinary Shares - Class A

WeShop Holdings Limited

WeShop Holdings Limited is attracting significant community attention as a high-volatility, low-float play, with traders actively debating its potential for rapid short squeezes and comparing its price action to other trending micro-cap momentum stocks. While some investors view the current activity as a prime setup for explosive gains driven by limited supply and high borrowing costs, skeptics warn of structural risks, including concerns over cash reserves and the high likelihood of a classic pump-and-dump scenario.

Newcourt Acquisition Corp. is a blank check company, which engages in the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded on February 25, 2021 and is headquartered in Oakland, CA.

Psyence Biomedical Ltd.

Psyence Biomedical is generating significant market activity as traders react to reports of a potential Trump administration executive order aimed at advancing psychedelic research for PTSD, which is fueling high-volatility price swings and speculation about a short squeeze on its low-float shares. While bulls are focused on the narrative of an emerging sector catalyst and the potential for rapid gains, others in the community are voicing skepticism regarding the company's history of reverse splits and dilution, leading to intense debate over the stock's long-term sustainability.

Taiwan Semiconductor Manufacturing Co., Ltd. engages in the manufacture and sale of integrated circuits and wafer semiconductor devices. Its chips are used in personal computers and peripheral products, information applications, wired and wireless communications systems products, and automotive and industrial equipment including consumer electronics such as smartphones, digital television, game consoles, and digital cameras. The company was founded by Chung Mou Chang on February 21, 1987 and is headquartered in Hsinchu, Taiwan.

Taiwan Semiconductor Manufacturing - ADR

Taiwan Semiconductor is trending as investors digest record-breaking revenue figures driven by relentless AI chip demand, while the broader community debates whether recent price volatility is a prime entry opportunity or a sign of heightened geopolitical and supply chain risks. While some traders are capitalizing on institutional accumulation patterns, others are closely monitoring supply constraints such as helium shortages and energy infrastructure bottlenecks that could pressure margins.

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is trending as the stock builds momentum behind a series of positive analyst upgrades and reports of strong internal growth targets, including the launch of the ES9 SUV. While bulls are focused on long-term expansion and the potential for a short squeeze as institutional confidence grows, community discussion remains heavily divided between those highlighting these fundamental improvements and those concerned about persistent price volatility and market maker influence.

Julong Holding Ltd. engages in the business of investment holding activities. It provides intelligent integrated solutions to public utilities, enterprises, commercial, and multifamily properties. The company was founded by Jia Qi Hu on August 07, 2023 and is headquartered in Beijing, China.

Julong Holding Ltd. - Ordinary Shares - Class A

Julong Holding Ltd. is trending as a low-float Chinese micro-cap play, drawing significant attention from day traders seeking quick momentum and potential short squeezes. Community discussions are highly polarized, with many retail participants speculating on parabolic moves and comparing the stock to past market runners, while others warn of the inherent risks associated with high volatility and the potential for rapid price reversals.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Equities Analysts Offer Predictions for UNCY Q1 Earnings

Unicycive Therapeutics, Inc. (NASDAQ:UNCY - Free Report) - Analysts at Brookline Capital Markets issued their Q1 2026 earnings per share estimates for Unicycive Therapeutics in a research note issued on Tuesday, April 7th. Brookline Capital Markets analyst K. Raja expects that the company will post...

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Given Consensus Rating of "Moderate Buy" by Brokerages

Unicycive Therapeutics, Inc. (NASDAQ:UNCY - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the five ratings firms that are currently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation and four have assi...

Kuehn Law Encourages Investors of Unicycive Therapeutics, Inc. to Contact Law Firm

Kuehn Law Encourages Investors of Unicycive Therapeutics, Inc. to Contact Law Firm Kuehn Law Encourages Investors of Unicycive Therapeutics, Inc. to Contact Law Firm PR Newswire NEW YORK, April 9, 2026 NEW YORK, April 9, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is...

Brookline Capital Markets Estimates UNCY Q2 Earnings

Unicycive Therapeutics, Inc. (NASDAQ:UNCY - Free Report) - Brookline Capital Markets issued their Q2 2026 earnings per share estimates for shares of Unicycive Therapeutics in a report issued on...

Benchmark Cuts Unicycive Therapeutics (NASDAQ:UNCY) Price Target to $15.00

Benchmark lowered their target price on shares of Unicycive Therapeutics from $21.00 to $15.00 and set a "speculative buy" rating for the company in a research note on Monday...

HC Wainwright Issues Positive Estimate for UNCY Earnings

Unicycive Therapeutics, Inc. (NASDAQ:UNCY - Free Report) - Equities research analysts at HC Wainwright increased their Q1 2026 EPS estimates for Unicycive Therapeutics in a note issued to investors on Tuesday, March 31st. HC Wainwright analyst S. Ramakanth now anticipates that the company will post...

Guggenheim Has Lowered Expectations for Unicycive Therapeutics (NASDAQ:UNCY) Stock Price

Guggenheim decreased their price target on Unicycive Therapeutics from $46.00 to $40.00 and set a "buy" rating on the stock in a research note on Thursday...

Noble Financial Has Positive Forecast for UNCY Q1 Earnings

Unicycive Therapeutics, Inc. (NASDAQ:UNCY - Free Report) - Equities research analysts at Noble Financial increased their Q1 2026 earnings per share (EPS) estimates for shares of Unicycive...

<ul class="summary-bullets"><li>The FDA is expected to decide on the application by June 29, as per the company.&nbsp;</li><li>The FDA in June refused to approve the company’s application citing manufacturing issues at a third-party manufacturing vendor.&nbsp;</li><li>The company is now looking to launch OLC in the third quarter.</li></ul>Shares of Unicycive Therapeutics Inc (UNCY) jumped 9% on Wednesday as retail investors contemplated the possibility of approval for the company’s Oxylanthanum carbonate.UNCY has resubmitted its application seeking the U.S. Food and Drug Administration’s approval for Oxylanthanum carbonate for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis following a previous rejection. The FDA is expected to decide on the application by June 29, as per the company.The FDA in June refused to approve the company’s application citing manufacturing issues at a third-party manufacturing vendor.The company is now looking to launch OLC in the third quarter and is continuing to strengthen its commercial infrastructure and advance market readiness initiatives in the meantime.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around UNCY jumped from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume increased from ‘normal’ to ‘high’ levels. Over the past week, message volume rose 150%, according to Stocktwits data.A Stocktwits user predicted revenue of as much as $600 million for OLC in 2029.<stembedurl>https://www.stocktwits.com/Thrasher5699/message/649190093</stembedurl>Yet another sees 80% chances for the drug’s approval this time.<stembedurl>https://www.stocktwits.com/Cvfiore2001/message/649096819</stembedurl><h2 class="st-heading-2">Unicycive Therapeutics Inc Management Commentary</h2>“This year is shaping up to be pivotal for Unicycive, underscored by the U.S. Food and Drug Administration’s acceptance of our New Drug Application resubmission for OLC and the potential for approval and launch later this year,” said CEO Shalabh Gupta earlier this week. “With hyperphosphatemia still uncontrolled in nearly 75% of U.S. patients with chronic kidney disease undergoing dialysis, OLC, if approved, has the potential to offer a meaningful new treatment option characterized by a differentiated clinical profile and reduced pill burden compared to currently available phosphate binders.”Hyperphosphatemia is a condition characterized by excessively high levels of phosphate in the blood.<a href="https://stocktwits.com/symbol/UNCY">UNCY stock </a>has gained nearly 32% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/lly-stock-rallies-on-much-awaited-fda-approval-for-weight-loss-pill/cZ7Hp5ORIF5">LLY Stock Rallies On Much Awaited FDA Approval For Weight Loss Pill</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.<div class="st-video-embed" data-video-url="https://videos.stocktwits-cdn.com/hls/2026/03/26/69ee8298-8c28-42e1-b686-43e84dc29610/fq6gh7vs9vzzy7rkkx2fll5vlsu3_download.mp4" data-thumbnail-url="" data-caption="" data-summary="" data-width="" data-height="" data-orientation="horizontal" data-duration="">&nbsp;</div>

Rising stock market chart on a trading board background.

UNCY Retail Buzz Explodes 150% This Week as Traders Bet Big on Experimental Drug Approval

UNCY has resubmitted its application seeking the U.S. Food and Drug Administration’s approval for Oxylanthanum carbonate for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis. 

Equity

UNCY has resubmitted its application seeking the U.S. Food and Drug Administration’s approval for Oxylanthanum carbonate for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis. 


Noble Financial Brokers Boost Earnings Estimates for UNCY

Unicycive Therapeutics, Inc. (NASDAQ:UNCY - Free Report) - Stock analysts at Noble Financial increased their Q3 2026 earnings per share estimates for Unicycive Therapeutics in a research report...

Unicycive Therapeutics, Inc. is a biotechnology company, which engages in developing novel treatments for kidney diseases. The firm investigational treatment is oxylanthanum carbonate, a novel phosphate binding agent currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of hyperphosphatemia in patients with chronic kidney disease who are on dialysis. Unicycive’s second investigational treatment UNI-494 is intended for the treatment of conditions related to acute kidney injury. It has been granted orphan drug designation (ODD) by the FDA for the prevention of Delayed Graft Function (DGF) in kidney transplant patients and has completed a Phase 1 dose-ranging safety study in healthy volunteers. The company was founded by Shalabh Gupta on August 18, 2016 and is headquartered in Los Altos, CA.

UNCY
Unicycive Therapeutics Inc

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest UNCY News

UNCYUnicycive Therapeutics Inc